Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 8:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Concurrent Radiotherapy Clear all
Active, not recruiting Phase 1 Interventional

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

NCT05411094
View directory record Official record
Conditions
Locally Advanced Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Unresectable Pancreatic Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Durvalumab, Magnetic Resonance Imaging, Olaparib
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
10
States / cities
Irvine, California • Los Angeles, California • Orange, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 19, 2026, 8:16 AM EDT
Completed Phase 2 Interventional Results available

Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery

NCT00601627
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
panitumumab, capecitabine, fluorouracil, gemcitabine hydrochloride, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
281
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 173 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Sep 19, 2026, 8:16 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B

NCT03778879
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Pancreas Cancer
Interventions
CCX872-B
Drug
Lead sponsor
Alan Katz
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Sep 19, 2026, 8:16 AM EDT
Completed Phase 2 Interventional

Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer

NCT00318903
View directory record Official record
Conditions
Esophageal Cancer, Cancer of the Esophagus, Esophagus Cancer, Esophageal Neoplasm, Cancer of Esophagus
Interventions
Irinotecan (drug), Taxotere (drug), Radiotherapy (procedure), Esophagectomy (procedure)
Drug · Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Sep 19, 2026, 8:16 AM EDT
Not listed Phase 2 Interventional

An Efficacy and Safety Study to Assess [18F]-ML-10 in Detecting Response of Tumors to Chemotherapy and Radiation

NCT01260480
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms
Interventions
[18F]-ML-10 in conjunction with PET imaging
Other
Lead sponsor
Aposense Ltd.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
4
States / cities
Boston, Massachusetts • Teaneck, New Jersey • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2010 · Synced Sep 19, 2026, 8:16 AM EDT
Withdrawn Phase 2 Interventional

Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

NCT05743270
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
RP3, CCRT(concurrent chemoradiation therapy), carboplatin and paclitaxel, nivolumab
Biological · Other
Lead sponsor
Replimune, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • Iowa City, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 19, 2026, 8:16 AM EDT
Completed Phase 2 Interventional Results available

Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo

NCT03421652
View directory record Official record
Conditions
Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
Interventions
Nivolumab, Radiation
Drug · Radiation
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Detroit, Michigan • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Sep 19, 2026, 8:16 AM EDT
Terminated Phase 3 Interventional Results available

Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer

NCT02049151
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Tecemotide, Placebo, Cyclophosphamide (CPA), Saline (sodium chloride)
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Sep 19, 2026, 8:16 AM EDT
Completed Phase 1 Interventional

TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer

NCT04104139
View directory record Official record
Conditions
Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8
Interventions
3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Trifluridine and Tipiracil Hydrochloride
Radiation · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 19, 2026, 8:16 AM EDT
Completed Phase 2 Interventional Results available

Induction Chemotherapy Followed by Chemoradiotherapy for Head and Neck Cancer

NCT01716195
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Induction Chemotherapy followed by Response Adapted Chemoradiation
Radiation
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Sep 19, 2026, 8:16 AM EDT
Terminated Phase 2 Interventional Results available

Induction Chemo-Nivo in Unresectable Stage III NSCLC

NCT06003075
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell, Lung Cancer Stage III
Interventions
Nivolumab and Chemotherapy, Nivolumab, Post Induction Surgery, Post Induction XRT
Combination Product · Drug · Procedure + 1 more
Lead sponsor
Ralph G Zinner
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 19, 2026, 8:16 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

NCT05353257
View directory record Official record
Conditions
Limited-Stage Small Cell Lung Cancer
Interventions
HLX10, carboplatin/cisplatin-etoposide, Thoracic radiotherapy, Placebo, Prophylactic Cranial Irradiation (PCI)
Drug · Radiation
Lead sponsor
Shanghai Henlius Biotech
Industry
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
31
States / cities
Arcadia, California • Los Alamitos, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 19, 2026, 8:16 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer

NCT04866017
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Tislelizumab, Durvalumab, Ociperlimab, Chemotherapy, Radiotherapy
Drug · Radiation
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bolivar, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 19, 2026, 8:16 AM EDT
Withdrawn Not applicable Interventional

Phase I Study MR-guided SBRT to PCa

NCT03935308
View directory record Official record
Conditions
Low or Intermediate Risk Prostate Cancer
Interventions
MR guided Linear Accelerator
Radiation
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Sep 19, 2026, 8:16 AM EDT
Terminated Phase 1 Interventional

Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor)

NCT00630890
View directory record Official record
Conditions
Cholangiocarcinoma, Klatskin Tumor, Biliary Tract Cancer
Interventions
External beam radiation and Cyberknife radiosurgery boost and capecitabine
Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2015 · Synced Sep 19, 2026, 8:16 AM EDT
Completed Phase 3 Interventional

Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery

NCT00003387
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, chemotherapy, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
47
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Sep 19, 2026, 8:16 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

NCT00020709
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
cisplatin, docetaxel, etoposide, gefitinib, radiation therapy, placebo
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Sep 19, 2026, 8:16 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer

NCT00068575
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Recombinant Interferon Alfa, Cisplatin, Fluorouracil, Radiation Therapy
Biological · Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Sep 19, 2026, 8:16 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT00334815
View directory record Official record
Conditions
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma, Minimally Invasive Lung Adenocarcinoma, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Interventions
Bevacizumab, Cisplatin, Docetaxel, Etoposide, Filgrastim, Pegfilgrastim, Radiation Therapy
Biological · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2027
U.S. locations
61
States / cities
Mobile, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 19, 2026, 8:16 AM EDT
Withdrawn Phase 2 Interventional

Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer

NCT03628144
View directory record Official record
Conditions
Non Small Cell Lung Cancer, NSCLC, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage ⅢA, NSCLC Stage IIIB, NSCLC, Stage IIIA
Interventions
Impact® Advanced Recovery, Boost® High Protein, Radiation Therapy, Chemotherapy, Quality of life (EORTC-QLQ-30), Evaluation of Cognitive Function (FACT-Cog, v. 3.0), Mindfulness Questionnaire (FFMQ)
Dietary Supplement · Radiation · Drug + 1 more
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Sep 19, 2026, 8:16 AM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer

NCT00265941
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cetuximab, cisplatin, Accelerated Fractionation by Concomitant Boost, Intensity-modulated radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2022
U.S. locations
363
States / cities
Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 255 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Sep 19, 2026, 8:16 AM EDT
Completed Phase 2 Interventional Results available

De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca

NCT01530997
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
Interventions
Intensity Modulated Radiotherapy (IMRT), Cisplatin, Limited surgical evaluation
Radiation · Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
5
States / cities
Colorado Springs, Colorado • Gainesville, Florida • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Sep 19, 2026, 8:16 AM EDT
Terminated Phase 1 Interventional

Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma

NCT03246113
View directory record Official record
Conditions
Glioblastoma
Interventions
Cannabis, Temozolomide, Radiation Therapy
Drug · Radiation
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Sep 19, 2026, 8:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer

NCT02990468
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
BMX-001, Radiation Therapy, Cisplatin
Drug · Radiation
Lead sponsor
BioMimetix JV, LLC
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
San Francisco, California • Gainesville, Florida • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Sep 19, 2026, 8:16 AM EDT